Valbenazine - Neurocrine Biosciences

Drug Profile

Valbenazine - Neurocrine Biosciences

Alternative Names: INGREZZA; MT 5199; NBI-98854; Valbenazine-tosylate; VMAT2-inhibtor-Neurocrine-Biosciences

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurocrine Biosciences
  • Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences
  • Class 3-ring heterocyclic compounds; Amino acids; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Drug-induced dyskinesia
  • Phase II Gilles de la Tourette's syndrome
  • Discontinued Huntington's disease; Schizophrenia

Most Recent Events

  • 04 Dec 2017 Adverse events data from a pooled analysis of phase II and III KINECT, KINECT 2 and KINECT 3 trials in Drug-induced dyskinesia released by Neurocrine Biosciences
  • 04 Dec 2017 Safety and efficacy data from the phase III KINECT 4 trial in Drug-induced dyskinesia released by Neurocrine Biosciences
  • 25 Oct 2017 Neurocrine Biosciences initiates the phase IIb T-Force GOLD study in Gilles de la Tourette's syndrome (In adolescents, In children) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top